Skip to content

Endocrine · Reference monograph

GnRH antagonist used mainly in advanced prostate cancer

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Degarelix is a third-generation gonadotropin-releasing hormone antagonist developed by Ferring Pharmaceuticals and approved by the FDA in 2008 and subsequently in the EU. It is a synthetic decapeptide containing several unnatural amino acids, engineered to block the GnRH receptor while avoiding the histamine-release problems that limited earlier antagonist designs. It is marketed as Firmagon for advanced prostate cancer.

Degarelix is of particular research interest because it suppresses the pituitary-gonadal axis without the initial hormonal surge seen with GnRH agonists such as leuprorelin. This makes it a valuable comparator for studying whether the agonist flare matters biologically, and how rapidly androgen deprivation can be achieved in experimental systems. Comparative trials with agonists have also examined secondary endpoints such as FSH suppression and cardiovascular events, questions that remain an active area of investigation. In in vitro studies and animal models.">preclinical work, degarelix provides a clean tool for receptor blockade in models of hormone-dependent tumour growth and reproductive physiology.

Mechanism studied

  1. Degarelix
  2. GnRH receptor blockade
  3. LH & FSH ↓
  4. Testosterone ↓

Degarelix binds competitively and reversibly to GnRH receptors on pituitary gonadotrophs, preventing endogenous GnRH from activating them. Because the receptor is blocked rather than stimulated, there is no initial release of luteinising hormone or follicle-stimulating hormone. Circulating LH and FSH therefore fall promptly, followed by a rapid decline in testosterone in published studies. Unlike agonists, degarelix does not depend on receptor desensitisation, so suppression begins without delay. Its formulation forms a slow-releasing depot after administration, a property that has been studied as a model of self-assembling peptide release. Its notably deeper FSH suppression is under ongoing investigation.

Research highlights

  • 01Designed in the 1990s and 2000s to overcome histamine-releasing effects that limited earlier GnRH antagonist peptides.
  • 02A pivotal comparative trial with leuprolide established degarelix as a reference flare-free comparator in prostate cancer research.
  • 03Its self-assembling depot behaviour has attracted interest in peptide formulation science.
  • 04Used preclinically to dissect the effects of immediate versus delayed androgen deprivation.
  • 05The relative cardiovascular profile of antagonists versus agonists remains an open, actively studied question.

Latest published research

384 papers on PubMed →

  1. Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer

    Virtanen I et al. · International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 Dec · PMID 42733361

  2. Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system

    Li G et al. · International urology and nephrology · 2026 Nov · PMID 42154420

  3. Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study

    Titus RS et al. · Urologic oncology · 2026 Oct 18 · PMID 42892580

  4. An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation

    Robotham A et al. · bioRxiv : the preprint server for biology · 2026 Oct 9 · PMID 42926518

  5. Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan

    Kawahara T et al. · Cancer reports (Hoboken, N.J.) · 2026 Sep · PMID 42728640

  6. Prostate cancer-associated Trousseau's syndrome presenting as stroke in a 42-year-old man

    Tsukii Y et al. · Urology case reports · 2026 Sep · PMID 42518671

  7. A novel model to study the impact of gender-affirming therapy on bone in young male mice

    Verlinden L et al. · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026 Aug 21 · PMID 41543142

  8. Disproportionality analysis of adverse events associated with degarelix: a real-world study from the FDA Adverse Event Reporting System (FAERS) database

    Lin X et al. · Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 Aug · PMID 41776145

Live feed from PubMed (NCBI) for “Degarelix”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

170 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Degarelix”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]Klotz et al., 2008 — BJU Int
  3. [3]WADA — Prohibited List of Substances and Methods

FAQ

  • Degarelix blocks the GnRH receptor directly, whereas agonists first stimulate and then desensitise it. As a result, degarelix lowers LH, FSH and testosterone without the initial flare that agonists such as leuprorelin or goserelin produce.

  • Early antagonist peptides caused histamine release from mast cells. Medicinal chemists introduced unnatural residues to retain strong receptor blockade while reducing that effect and improving stability, an approach exemplified by degarelix.

  • Degarelix is approved by the FDA and EMA as a prescription medicine for advanced prostate cancer. Research-grade material is intended only for laboratory studies of GnRH receptor pharmacology and endocrine models.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp